The immune-suppressing drug rapamycin, originally used for kidney transplants, is gaining attention for its potential to slow aging.
The immune-suppressing drug rapamycin, originally used for kidney transplants, is gaining attention for its potential to slow aging.
There are one or two countries outside the US that can approve drugs for use.
Indeed there are, but just under half of all of medical studies performed world wide are performed in the States, roughly half of the world’s pharmaceutical companies based in the States, and the US has consistently lead the world in medical innovations, with almost 50 percent more innovations than from the EU and Switzerland combined.
My point is not to sound US centric, but to say there is a lot of capital and willpower in the US pharmaceutical industry, and without that willpower it will be significantly harder to get rapamycin accepted as a viable longevity drug.